32 related articles for article (PubMed ID: 18452099)
1. The Impact of Tumor Hypoxia Modulation on sIL-2R Levels in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients Undergoing Chemotherapy: A Randomized Clinical Trial.
Rizky D; Tandarto K; Pangarsa EA; Naibaho RM; Kurniawan SP; Santosa D; Setiawan B; Suharti C
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1315-1324. PubMed ID: 38679992
[TBL] [Abstract][Full Text] [Related]
2. How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials.
Intzes S; Symeonidou M; Zagoridis K; Pentidou A; Bezirgianidou Z; Papoutselis M; Misidou C; Roumpakis C; Spanoudaki A; Liapis K; Spanoudakis E
Ann Hematol; 2024 May; 103(5):1623-1633. PubMed ID: 38191715
[TBL] [Abstract][Full Text] [Related]
3. Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model.
Sullivan MR; White RP; Dashnamoorthy Ravi ; Kanetkar N; Fridman IB; Ekenseair A; Evens AM; Konry T
Cell Death Dis; 2024 Jan; 15(1):18. PubMed ID: 38195589
[TBL] [Abstract][Full Text] [Related]
4. Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study.
Ikeda D; Oura M; Uehara A; Tabata R; Narita K; Takeuchi M; Machida Y; Matsue K
Blood Adv; 2024 Apr; 8(8):1893-1897. PubMed ID: 38359408
[No Abstract] [Full Text] [Related]
5. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.
Kikuchi Y; Shimada H; Yamasaki F; Yamashita T; Araki K; Horimoto K; Yajima S; Yashiro M; Yokoi K; Cho H; Ehira T; Nakahara K; Yasuda H; Isobe K; Hayashida T; Hatakeyama S; Akakura K; Aoki D; Nomura H; Tada Y; Yoshimatsu Y; Miyachi H; Takebayashi C; Hanamura I; Takahashi H
Int J Clin Oncol; 2024 May; 29(5):512-534. PubMed ID: 38493447
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy.
Shirouchi Y; Nishimura N; Mishima Y; Ishihara Y; Asai H; Tamba M; Hirano M; Hirano K; Teramoto Y; Yoshida K; Takeuchi K; Terauchi T; Maruyama D
Sci Rep; 2023 Aug; 13(1):13713. PubMed ID: 37608029
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients.
Shi Q; Shen R; Wang CF; Fan X; Qian Y; Ou-Yang BS; Zhao Y; Leboeuf C; Janin A; Cheng S; Wang L; Zhao WL
Mediators Inflamm; 2017; 2017():7960907. PubMed ID: 29109622
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.
Witzig TE; Maurer MJ; Stenson MJ; Allmer C; Macon W; Link B; Katzmann JA; Gupta M
Am J Hematol; 2014 Apr; 89(4):417-22. PubMed ID: 24382707
[TBL] [Abstract][Full Text] [Related]
9. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.
Yang ZZ; Grote DM; Ziesmer SC; Manske MK; Witzig TE; Novak AJ; Ansell SM
Blood; 2011 Sep; 118(10):2809-20. PubMed ID: 21719603
[TBL] [Abstract][Full Text] [Related]
10. SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.
Tomita N; Sakai R; Fujisawa S; Fujimaki K; Taguchi J; Hashimoto C; Ogawa K; Yamazaki E; Ishigatsubo Y
Cancer Sci; 2012 Aug; 103(8):1518-23. PubMed ID: 22587388
[TBL] [Abstract][Full Text] [Related]
11. The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis.
Hu C; Deng C; Zou W; Zhang G; Wang J
Acta Haematol; 2015; 134(2):111-8. PubMed ID: 25925586
[TBL] [Abstract][Full Text] [Related]
12. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.
Westin JR; Fayad LE
Curr Hematol Malig Rep; 2009 Oct; 4(4):218-24. PubMed ID: 20425411
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy.
Oki Y; Kato H; Matsuo K; Kuwatsuka Y; Taji H; Yamamoto K; Kagami Y; Morishima Y
Leuk Lymphoma; 2008 Jul; 49(7):1345-51. PubMed ID: 18452099
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
